GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Horizon Therapeutics PLC (NAS:HZNP) » Definitions » PB Ratio

Horizon Therapeutics (Horizon Therapeutics) PB Ratio : 5.01 (As of Apr. 26, 2024)


View and export this data going back to 2011. Start your Free Trial

What is Horizon Therapeutics PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-04-26), Horizon Therapeutics's share price is $116.30. Horizon Therapeutics's Book Value per Share for the quarter that ended in Jun. 2023 was $23.20. Hence, Horizon Therapeutics's PB Ratio of today is 5.01.

The historical rank and industry rank for Horizon Therapeutics's PB Ratio or its related term are showing as below:

HZNP' s PB Ratio Range Over the Past 10 Years
Min: 1.07   Med: 3.34   Max: 14.9
Current: 5.01

During the past 13 years, Horizon Therapeutics's highest PB Ratio was 14.90. The lowest was 1.07. And the median was 3.34.

HZNP's PB Ratio is not ranked
in the Drug Manufacturers industry.
Industry Median: 1.945 vs HZNP: 5.01

During the past 12 months, Horizon Therapeutics's average Book Value Per Share Growth Rate was 8.00% per year. During the past 3 years, the average Book Value Per Share Growth Rate was 24.30% per year. During the past 5 years, the average Book Value Per Share Growth Rate was 33.70% per year.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Horizon Therapeutics was 68.60% per year. The lowest was -5.00% per year. And the median was 23.65% per year.

Back to Basics: PB Ratio


Horizon Therapeutics PB Ratio Historical Data

The historical data trend for Horizon Therapeutics's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Horizon Therapeutics PB Ratio Chart

Horizon Therapeutics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.77 3.11 4.02 5.24 5.10

Horizon Therapeutics Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.71 2.81 5.10 4.90 4.43

Competitive Comparison of Horizon Therapeutics's PB Ratio

For the Drug Manufacturers - General subindustry, Horizon Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Horizon Therapeutics's PB Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Horizon Therapeutics's PB Ratio distribution charts can be found below:

* The bar in red indicates where Horizon Therapeutics's PB Ratio falls into.



Horizon Therapeutics PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Horizon Therapeutics's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Jun. 2023)
=116.30/23.198
=5.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Horizon Therapeutics  (NAS:HZNP) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Horizon Therapeutics PB Ratio Related Terms

Thank you for viewing the detailed overview of Horizon Therapeutics's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Horizon Therapeutics (Horizon Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
70 St. Stephen’s Green, Dublin, IRL, D02 E2X4
Horizon Therapeutics PLC is a biotechnology company. The company is focused on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. Some of its pipeline products include UPLIZNA; HZN-825; Dazodalibep; Daxdilimab; TEPEZZA and others.
Executives
Andy Pasternak officer: EVP and Chief Business Officer C/O HORIZON THERAPEUTICS PLC, CONNAUGHT HOUSE, 1ST FL, 1 BURLINGTON RD, DUBLIN L2 D04 C5Y6
Aaron Cox officer: EVP, Chief Financial Officer C/O HORIZON THERAPEUTICS PLC, 70 ST. STEPHEN'S GREEN, DUBLIN L2 D02 E2X4
Jeffrey W Sherman officer: EVP & Chief Medical Officer C/O IDM PHARMA, INC., 9 PARKER, SUITE 100, IRVINE CA 92618
Patrick Mcilvenny officer: Chief Accounting Officer C/O HORIZON THERAPEUTICS PLC, 70 ST. STEPHEN'S GREEN, DUBLIN L2 D02 E2X4
Sean M. Clayton officer: EVP, General Counsel C/O HORIZON THERAPEUTICS PLC, 70 SAINT STEPHENS GREEN, DUBLIN L2 D02 E2X4
Thompson Elizabeth H.z. officer: EVP, Research & Development C/O HORIZON THERAPEUTICS, INC., 2 TOWER PLACE, 12TH FLOOR, SOUTH SAN FRANCISCO CA 94080
Timothy P Walbert director, officer: President, Chairman and CEO 1033 SKOKIE BOULEVARD, SUITE 355, NORTHBROOK IL 60062
Jacopo Leonardi officer: Chief Commercial Officer C/O HORIZON THERAPEUTICS PLC, 70 ST. STEPHEN'S GREEN, DUBLIN L2 D02 E2X4
Paul W. Hoelscher officer: EVP Finance 1 HORIZON WAY, C/O HORIZON THERAPEUTICS, INC., DEERFIELD IL 60015
Michael A. Desjardin officer: EVP, Technical Operations C/O JAZZ PHARMACEUTICALS, INC., 3180 PORTER DRIVE, PALO ALTO CA 94304
Miles W Mchugh officer: Principal Accounting Officer C/O ACCRETIVE HEALTH, INC., 401 N. MICHIGAN AVE, SUITE 2700, CHICAGO IL 60611
Barry Moze officer: EVP, Corporate Dev't. C/O HORIZON PHARMA, INC., 520 EAST COOK ROAD, SUITE 520, DEERFIELD IL 60015
Brian K Beeler officer: EVP, General Counsel C/O HORIZON PHARMA PLC, 520 LAKE COOK ROAD, SUITE 520, DEERFIELD IL 60015
Michael G Grey director C/O SGX PHARMACEUTICALS, INC., 10505 ROSELLE STREET, SAN DIEGO CA 92121
William F Daniel director TREASURY BUILDING, LOWER GRAND CANAL STREET, DUBLIN 2 L2 00000